BUSCOPANVET 20MG/ML SOLUTION FOR INJECTION
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
02-05-2024
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
HYOSCINE BUTYLBROMIDE
Available from:
Boehringer Ingelheim Ltd
ATC code:
QA03BB01
INN (International Name):
HYOSCINE BUTYLBROMIDE
Dosage:
20 Mg/Ml
Pharmaceutical form:
Solution for Injection
Prescription type:
POM
Therapeutic group:
Bovine, Equine - Food
Therapeutic area:
Butylscopolamine
Therapeutic indications:
Neurological Preparations
Authorization status:
Authorised
Authorization date:
2003-09-05
Summary of Product characteristics
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Buscopanvet 20 mg/ml solution for injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Colourless solution for injection
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Horses and calves
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
HORSE:
The product is indicated for antispasmodic treatment in case of equine colic.
CALF:
The product is indicated for its antispasmodic effect, as an aid to the symptomatic treatment of calf scour. Oral re-
hydration and other appropriate therapy must also be administered as required.
4.3 CONTRAINDICATIONS
Do not use in horses suffering from paralytic ileus.
Do not use in horses less than 6 weeks of age.
See also section 4.11 Withdrawal periods and section 4.7 for use during pregnancy.
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Each ml contains:
ACTIVE SUBSTANCE
Hyoscine butylbromide
20 mg
(Equivalent to 16.32 mg butylhyoscine)
EXCIPIENTS
Methyl parahydroxybenzoate (E 218)
1.8 mg
Propyl parahydroxybenzoate (E 216)
0.2 mg
For a full list of excipients, see section 6.1.
IRISH MEDICINES BOARD
________________________________________________________________________________________________________________________
_Date Printed 28/02/2011_
_CRN 7010045_
_page number: 1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
In case of no clinical response the necessity for surgical intervention should be taken into consideration. See also
section 4.11 Withdrawal periods.
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Horses should be monitored carefully following treatment. If the response to treatment with the product is poor, careful
re-evaluation of the diagnosis should be made and the possibility of surgical inter
Read the complete document
